CHALLENGE. A Randomised Clinical Trial Examining Virtual Reality Therapy

Auditory hallucinations are among the most frequent symptoms in psychotic disorders. While a large group of patients with first episode psychosis achieve remission of psychotic symptoms during first year after initial contact with mental health services, almost one third continue having psychotic symptoms in spite of treatment with antipsychotic medication. Since auditory hallucinations are a major cause of distress and suffering for these patients, there is an essential need to test the effectives of targeted psychotherapeutic interventions in alleviating auditory hallucinations Two previous trials have provided preliminary evidence of the effectiveness of virtual reality therapy on auditory hallucinations, but no trial to date has examined the effect of virtual reality assisted therapy in an adequately powered RCT. In this large-scale randomized, clinical trial, patients in the experimental intervention will be receiving 7 sessions of virtual reality assisted avatar therapy while patients in the control group will receive 7 sessions of supportive contact with mental health care professionals at their regular outpatient clinic.

If the virtual reality therapy is found to be beneficial in reducing the severity of refractory auditory hallucinations, it will be a breakthrough in the current treatment of psychotic disorders. A large group of patients with schizophrenia and related disorders in Denmark and worldwide will be the target group of the therapy. If proven effective, the treatment will be especially relevant for patients with treatment resistant schizophrenia, but the treatment can also be used as an add on to antipsychotic medication for patients with a better prognosis, such as patients with first episode psychosis. If the virtual reality therapy is proven effective, it can be implemented in mental health services in Denmark and internationally. A successful implementation could reduce the costs associated with treatment of schizophrenia.

Inclusion criteria

• Age 18 - years
• Ability to give informed consent
• A schizophrenia spectrum disorder (ICD-10 code: F20 -F29)
• Auditory hallucinations for at least three months, corresponding to a SAPS score on auditory hallucinations of ≥3.
• No changes in antipsychotic medication within the past four weeks and

• Not responding to current antipsychotic compound or
• Not responding to at least two antipsychotic compounds. Table2

Exclusion criteria

• Rejecting informed consent
• Unable to identify a single dominant voice to work on
• A diagnosis of organic brain disease
• Substance to a level that hinders engagement in therapy.
• Auditory hallucinations in a language not spoken by the therapists
• A command of spoken Danish or English inadequate for engaging in therapy
• Inability to tolerate the assessment process
• Strongly impaired vision